Julia Yin

Julia Yin

Auto-generated profile, based on publicly available information

Julia Yin

School of Clinical Medicine, Faculty of Medicine, University of New South Wales (UNSW) Sydney, Kensington, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Science Advances
Verified
Journal Article
Open access
KMKendelle J. Murphy
Kendelle J. Murphy
DRDaniel A. Reed
Daniel A. Reed
CVClaire Vennin
Claire Vennin
JCJames Conway
James Conway
Max NobisMax Nobis
Max Nobis
PTPaul Timpson
Paul Timpson
Intravital imaging guides a personalized medicine approach to target mechanoreciprocity in pancreatic cancer.

5 July 2024 in Science Advances
Verified
Journal Article
Open access
BPBrooke Pereira
Brooke Pereira
SRShona Ritchie
Shona Ritchie
CCCecilia R. Chambers
Cecilia R. Chambers
KGKatie A. Gordon
Katie A. Gordon
AMAstrid Magenau
Astrid Magenau
PTPaul Timpson
Paul Timpson
Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrisome of the highly metastatic KPC ( Pdx1-Cre , LSL-Kras G12D/+ , LSL-Trp53 R172H/+ ) and poorly metastatic KP fl C ( Pdx1-Cre , LSL-Kras G12D/+ , Trp53 fl/+ ) genetically engineered mouse models of pancreatic cancer using mass spectrometry proteomics. Our assessment at early-, mid-, and late-stage disease reveals an increased abundance of nidogen-2 (NID2) in the KPC model compared to KP fl C, with further validation showing that NID2 is primarily expressed by cancer-associated fibroblasts (CAFs). Using biomechanical assessments, second harmonic generation imaging, and birefringence analysis, we show that NID2 reduction by CRISPR interference (CRISPRi) in CAFs reduces stiffness and matrix remodeling in three-dimensional models, leading to impaired cancer cell invasion. Intravital imaging revealed improved vascular patency in live NID2-depleted tumors, with enhanced response to gemcitabine/Abraxane. In orthotopic models, NID2 CRISPRi tumors had less liver metastasis and increased survival, highlighting NID2 as a potential PDAC cotarget.

15 April 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
TKThomas Kryza
Thomas Kryza
TKTashbib Khan
Tashbib Khan
SLScott Lovell
Scott Lovell
Brittney S. HarringtonBrittney S. Harrington
Brittney S. Harrington
JYJulia Yin
Julia Yin
JHJohn D. Hooper
John D. Hooper